Observational studyScientific reports2021
Clinical manifestations and visual outcomes associated with ocular toxoplasmosis in a Brazilian population.
Observational study in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Risk factors for recurrences and visual impairment in patients with ocular toxoplasmosis: A systematic review and meta-analysis.PloS one · 2023Pooled it
- Clinical and imaging characterization of ocular toxoplasmosis in a Central-West Brazilian population.International ophthalmology · 2026Article
- Risk Factors and Ocular Health Associated with Toxoplasmosis inMicroorganisms · 2026Article
- Interpretable multi-model deep learning framework for automated four-class diagnosis of ocular toxoplasmosis using fundus imaging.Scientific reports · 2025Article
- Intraocular Coinfection byPathogens (Basel, Switzerland) · 2025Article
- Direct genotype analysis of Toxoplasma gondii in ocular samples from patients with active rtinochoroiditis.BMC infectious diseases · 2025Article
- Common data elements for observational studies in ocular toxoplasmosis: a Delphi consensus.Journal of ophthalmic inflammation and infection · 2025Article
- A review of natural products as a source of next-generation drugs against apicomplexan parasites.npj antimicrobials and resistance · 2025Review
- Clinical Manifestations of Ocular Toxoplasmosis in Hubei, China: Case Series.Current medical science · 2025Article
- Human Retinal Organoid Model of Ocular Toxoplasmosis.Pathogens (Basel, Switzerland) · 2025Article
- Comparative evaluation of funduscopy, PCR and serology in the diagnosis of ocular toxoplasmosis at ECWA Eye Hospital, Kano.BMJ open ophthalmology · 2025Article
- Diseases Caused by and Behaviors Associated withPathogens (Basel, Switzerland) · 2024Review
- Clinical characteristics, visual acuity outcomes, and factors associated with loss of vision among patients with active ocular toxoplasmosis: A retrospective study in a Thai tertiary center.PLoS neglected tropical diseases · 2024Article
- Modulation of CXCL10 activity as a therapeutic target of ocular toxoplasmosis in diabetic mice.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2024Article
- The role of age in ocular toxoplasmosis: clinical signs of immunosenescence and inflammaging.Frontiers in medicine · 2024Article
- Outcomes of trimethoprim/ sulfamethoxazole treatment for ocular toxoplasmosis in Congolese patients.BMC ophthalmology · 2023Article
- Structure-activity relationships ofExpert opinion on drug discovery · 2022Article
- Posterior segment findings by spectral-domain optical coherence tomography and clinical associations in active toxoplasmic retinochoroiditis.Scientific reports · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ocular toxoplasmosis is the leading cause of posterior uveitis worldwide. We conducted an observational study of 262 consecutive individuals (n = 344 eyes) with ocular toxoplasmosis who were followed over a 34-month period. Most subjects were T. gondii IgG + /IgM- (n = 242; 92.4%; 317 eyes), and 140 eyes (40.7%) had active lesions. For eyes in which retinal lesions were active at recruitment and best-corrected visual acuity (BCVA) could be measured (n = 133), 21.0% (n = 28) remained blind (BCVA below 20/400) after inflammation resolved. In these eyes, atypical ocular toxoplasmosis (OR 4.99; 95% CI 1.14-22.85; p = 0.0330), macular lesion (OR 9.95; 95% CI 2.45-47.15; p = 0.0019) and any complication (OR 10.26; 95% CI 3.82-30.67; p < 0.0001) were associated with BCVA below 20/200. For eyes with only inactive lesions at recruitment and BCVA measured (n = 178), 28.1% (n = 50) were blind. In these eyes, having at least one lesion larger than one disc-diameter (OR 6.30; 95% CI 2.28-22.46; p = 0.0013) and macular lesion (OR 5.69; 95% CI 2.53-13.54; p < 0.0001) were associated with BCVA below 20/200. Older age (OR 1.02; 95% CI 1.00-1.05; p = 0.0493) and active disease at presentation (OR 4.74; 95% CI 1.95-12.91; p = 0.0011) were associated with recurrences. Additional clinical attention should be directed towards patients with risk factors for poor visual outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.